PMC3656679_01
a Administration of ipilimumab was accompanied by a temporary increase in serum LDH concentrations, followed by a slight but durable decrease over the next months. b Serum concentrations of the tumor marker S100 significantly dropped after administration of 4 cycles of ipilimumab, but subsequently started rising again after cessation of therapy, indicating a temporary initial reduction of total tumor burden.
cro-0006-0229-g01.jpg
PMC3656679_01_cro-0006-0229-g01.jpg
F1
Routine follow-up laboratory parameters remained mostly normal except for an isolated increase in serum lactate dehydrogenase (LDH) concentrations of up to 348 U/l during the initial 2 cycles of ipilimumab, which spontaneously resolved upon cessation of ipilimumab administration (fig. 1). Of interest, at this point, the tumor marker S100 had dropped from 0.24 microg/l before initiation of ipilimumab administration in December 2011 to 0.16 microg/l in April 2012 after 4 cycles of ipilimumab (fig. 1).